2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1094

EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases
Abstract Number: 1095

The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Abstract Number: 1096

Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks
Abstract Number: 1097

Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study
Abstract Number: 1098

Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Abstract Number: 1099

The Safety of Pulse Therapy- Systematic Review and Meta-analysis
Abstract Number: 1100

Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1101

Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database
Abstract Number: 1102

Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjogren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance
Abstract Number: 1103

Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US
Abstract Number: 1104

Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study
Abstract Number: 1105

Relationships Among Cognitive Emotion Regulation, Body Image, Family and Marital Function and Quality of Life in Chinese Female Patients with Systemic Lupus Erythematosus
Abstract Number: 1106

Systemic Lupus Erythematosus and Sjögren’s Syndrome in the Agricultural Health Study: Lower Risk Associated with Childhood Farm Residence and Raising Livestock
Abstract Number: 1107

Are Rheumatologists Correctly Identifying and Controlling Traditional Cardiovascular Risk Factors?
Abstract Number: 1108

Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].